BioCentury | Apr 8, 2021
Management Tracks

Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more

...executive director of the Clinical Trials Transformation Initiative (CTTI), a public-private partnership with FDA. Immuno-oncology play Arch Oncology Inc....
...Rahman stepped down as CSO of mAb developer CytoDyn Inc. (OTCQX:CYDY). BC Staff Tessera Therapeutics Inc. Syncona Ltd. Juvenescence Ltd. Medable Inc. Arch Oncology Inc. Mission...
BioCentury | Nov 19, 2020
Management Tracks

CStone’s Yeh joins Abbisko as CFO; plus moves at Ziopharm, Permira, Imara, Inivata, Topas and Arch

...financing co-led by new investors Vesalius BioCapital III and BioMedPartners, with participation from all existing investors. Arch Oncology Inc....
...served as general counsel and chief compliance officer. BC Staff Abbisko Therapeutics Co. Ltd. Ziopharm Oncology Inc. Imara Inc. Inivata Ltd. Arch Oncology Inc. Topas...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...is presenting its first-in-human clinical trial design for AK117.Arch Oncology Inc....
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...is presenting its first-in-human clinical trial design for AK117.Arch Oncology Inc....
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...thinks FSI-189 won’t show single-agent activity in cancer, but could be used in combination regimens. Arch Oncology Inc....
...IgG1 mAb rituximab, which targets B cell cancers. Innovent has not disclosed its strategy. 3) Arch Oncology Inc....
...the clinic have made it clear that tackling the target’s toxicity will be their priority. Arch Oncology Inc....
BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

...VP, head of nucleic acid therapies, external innovation at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Cancer company Arch Oncology Inc....
...was president and CMO of Furiex Pharmaceuticals Inc., which Amgen Inc. (NASDAQ:AMGN) acquired in 2014. BioCentury Staff Arch Oncology Inc. Cerevel...
BioCentury | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

...which is in a Phase I trial to treat solid tumors. President and CEO of Arch Oncology Inc....
...in 2016 (see "Tioma's Broad Basket" ). Chris Lieu, Staff Writer CD47 Signal regulatory protein alpha (SIRPA) (CD172a) (SHPS-1) AO-176 Arch Oncology Inc....
BioCentury | Aug 25, 2016
Targets & Mechanisms

Forty Seven and counting

...the Institute of Stem Cell Biology and Regenerative Medicine at Stanford. Last week's announcement by Tioma...
...for achieving a better, less toxic way of performing transplants has enormous potential," Uger said. Tioma...
...PFE), New York, N.Y. Stanford University, Stanford, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Tioma...
BioCentury | Aug 22, 2016
Finance

Tioma's broad basket

...clinical program targeting CD47 . President and CEO John Donovan said the round should enable Tioma...
...Venture Fund and SR One co-led the round. RiverVest's John McKearn, who will serve as Tioma's...
...functionally diverse portfolio and we're certainly prepared to move forward with more than one product." Tioma's...
BioCentury | Aug 22, 2016
Financial News

Tioma completes venture financing

Tioma Therapeutics Inc. , Brisbane, Calif. Business: Cancer Date completed: 2016-08-16 Type: Venture financing Raised: $86 million Investors: RiverVest Venture Partners; Novo Ventures; Roche Venture Fund; SR One WIR Staff...
Items per page:
1 - 10 of 11
BioCentury | Apr 8, 2021
Management Tracks

Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more

...executive director of the Clinical Trials Transformation Initiative (CTTI), a public-private partnership with FDA. Immuno-oncology play Arch Oncology Inc....
...Rahman stepped down as CSO of mAb developer CytoDyn Inc. (OTCQX:CYDY). BC Staff Tessera Therapeutics Inc. Syncona Ltd. Juvenescence Ltd. Medable Inc. Arch Oncology Inc. Mission...
BioCentury | Nov 19, 2020
Management Tracks

CStone’s Yeh joins Abbisko as CFO; plus moves at Ziopharm, Permira, Imara, Inivata, Topas and Arch

...financing co-led by new investors Vesalius BioCapital III and BioMedPartners, with participation from all existing investors. Arch Oncology Inc....
...served as general counsel and chief compliance officer. BC Staff Abbisko Therapeutics Co. Ltd. Ziopharm Oncology Inc. Imara Inc. Inivata Ltd. Arch Oncology Inc. Topas...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...is presenting its first-in-human clinical trial design for AK117.Arch Oncology Inc....
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...is presenting its first-in-human clinical trial design for AK117.Arch Oncology Inc....
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...thinks FSI-189 won’t show single-agent activity in cancer, but could be used in combination regimens. Arch Oncology Inc....
...IgG1 mAb rituximab, which targets B cell cancers. Innovent has not disclosed its strategy. 3) Arch Oncology Inc....
...the clinic have made it clear that tackling the target’s toxicity will be their priority. Arch Oncology Inc....
BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

...VP, head of nucleic acid therapies, external innovation at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Cancer company Arch Oncology Inc....
...was president and CMO of Furiex Pharmaceuticals Inc., which Amgen Inc. (NASDAQ:AMGN) acquired in 2014. BioCentury Staff Arch Oncology Inc. Cerevel...
BioCentury | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

...which is in a Phase I trial to treat solid tumors. President and CEO of Arch Oncology Inc....
...in 2016 (see "Tioma's Broad Basket" ). Chris Lieu, Staff Writer CD47 Signal regulatory protein alpha (SIRPA) (CD172a) (SHPS-1) AO-176 Arch Oncology Inc....
BioCentury | Aug 25, 2016
Targets & Mechanisms

Forty Seven and counting

...the Institute of Stem Cell Biology and Regenerative Medicine at Stanford. Last week's announcement by Tioma...
...for achieving a better, less toxic way of performing transplants has enormous potential," Uger said. Tioma...
...PFE), New York, N.Y. Stanford University, Stanford, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Tioma...
BioCentury | Aug 22, 2016
Finance

Tioma's broad basket

...clinical program targeting CD47 . President and CEO John Donovan said the round should enable Tioma...
...Venture Fund and SR One co-led the round. RiverVest's John McKearn, who will serve as Tioma's...
...functionally diverse portfolio and we're certainly prepared to move forward with more than one product." Tioma's...
BioCentury | Aug 22, 2016
Financial News

Tioma completes venture financing

Tioma Therapeutics Inc. , Brisbane, Calif. Business: Cancer Date completed: 2016-08-16 Type: Venture financing Raised: $86 million Investors: RiverVest Venture Partners; Novo Ventures; Roche Venture Fund; SR One WIR Staff...
Items per page:
1 - 10 of 11